A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, phase II, open label study of Apatinib Mesylate in patients with
Head and neck recurrent/metastatic adenoid cystic carcinoma (ACC). The primary purpose of
this study is to evaluate the efficacy and safety of Apatinib Mesylate in patients with ACC.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University